Macrophage activation by polysaccharide biological response modifier isolated from Aloe vera L. var. chinensis (Haw.) Berg.

International Immunopharmacology

Volumn 6, Issue 11, 2006, Pages 1634-1641

  Liu, C ^a   Leung, M Y K ^a   Koon, J C M ^a   Zhu, L F ^b   Hui, Y Z ^c   Yu, B ^c   Fung, K P ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SOUTH CHINA INSTITUTE OF BOTANY   (China)

^c SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

Author keywords

Aloe vera; Biological response modifier; Macrophage; Polysaccharides

Indexed keywords

ALOE VERA EXTRACT; BIOLOGICAL RESPONSE MODIFIER; FC RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NITRIC OXIDE; PAC I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALOE VERA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENDOCYTOSIS; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ALOE; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CELL LINE, TUMOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOLOGIC FACTORS; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PHAGOCYTOSIS; POLYSACCHARIDES; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748432397     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.04.013     Document Type: Article

References (48)

1. Naito M., Hasegawa G., and Takahashi K. Development, differentiation, and maturation of Kupffer cells. Microsc Res Tech 39 (1997) 350-364
2. Naito M. Macrophage heterogeneity in development and differentiation. Arch Histol Cytol 56 (1993) 331-351
3. Wu L., Vandenabeele S., and Georgopoulos K. Derivation of dendritic cells from myeloid and lymphoid precursors. Int Rev Immunol 20 (2001) 117-135
4. Roodman G.D. Cell biology of the osteoclast. Exp Hematol 27 (1999) 1229-1241
5. Cuadros M.A., and Navascues J. The origin and differentiation of microglial cells during development. Prog Neurobiol 56 (1998) 173-189
6. Unanue E.R. Perspective on antigen processing and presentation. Immunol Rev 185 (2002) 86-102
7. Murtaugh M.P., and Foss D.L. Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunophathol 87 (2002) 109-121
8. Neild A., Murata T., and Roy C.R. Processing and major histocompatibility complex class II presentation of Legionella pneumophila antigens by infected macrophages. Infect Immun 73 (2005) 2336-2343
9. Giacomini E., Iona E., Ferroni L., Miettinen M., Fattorini L., Orefici G., et al. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol 166 (2001) 7033-7041
10. Kelk P., Claesson R., Hanstrom L., Lerner U.H., Kalfas S., and Johansson A. Abundant secretion of bioactive interleukin-1beta by human macrophages induced by Actinobacillus actinomycetemcomitans leukotoxin. Infect Immun 73 (2005) 453-458
11. Charak B.S., Agah R., and Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 81 (1993) 3474-3479
12. Haidaris C.G., and Bonventre P.F. A role for oxygen-dependent mechanisms in killing of Leishmania donovani tissue forms by activated macrophages. J Immunol 129 (1982) 850-855
13. Mateo R.B., Reichner J.S., and Albina J.E. NO is not sufficient to explain maximal cytotoxicity of tumoricidal macrophages against an NO-sensitive cell line. J Leukoc Biol 60 (1996) 245-252
14. Remer K.A., Reimer T., Brcic M., and Jungi T.W. Evidence for involvement of peptidoglycan in the triggering of an oxidative burst by Listeria monocytogenes in phagocytes. Clin Exp Immunol 140 (2005) 73-80
15. Rilsgaard S., Rhodes J.M., and Bennedsen J. Macrophage activation by lymphokines and after direct contact with sensitized lymphocytes: histocompatibility requirements and the effect of inhibitors. Scand J Immunol 7 (1978) 209-213
16. Juy D., and Chedid L. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci U S A 72 (1975) 4105-4109
17. Krieg A.M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489 (1999) 107-116
18. Sironi M., Sica A., Riganti F., Licciardello L., Colotta F., and Mantovani A. Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int J Immunopharmacol 12 (1990) 397-402
19. Blackstock R., McElwee N., Neller E., and Shaddix-White J. Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells APC): requirements for GXM, APC activation, and interleukin-12. Infect Immun 68 (2000) 5146-5153
20. Heinzelmann M., Polk Jr. H.C., Chernobelsky A., Stites T.P., and Gordon L.E. Endotoxin and muramyl dipeptide modulate surface receptor expression on human mononuclear cells. Immunopharmacology 48 (2000) 117-128
21. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111 (2002) 927-930
22. Domer J., Elkins K., Ennist D., and Baker P. Modulation of immune responses by surface polysaccharides of Candida albicans. Rev Infect Dis 10 Suppl. 2 (1988) S419-S422
23. Blaschek W., Kasbauer J., Kraus J., and Franz G. Pythium aphanidermatum: culture, cell-wall composition, and isolation and structure of antitumour storage and solubilised cell-wall (1-3),(1-6)-beta-d-glucans. Carbohydr Res 231 (1992) 293-307
24. Leung M.Y., Fung K.P., and Choy Y.M. The isolation and characterization of an immunomodulatory and anti-tumor polysaccharide preparation from Flammulina velutipes. Immunopharmacology 35 (1997) 255-263
25. Garner R.E., and Hudson J.A. Intravenous injection of Candida-derived mannan results in elevated tumor necrosis factor alpha levels in serum. Infect Immun 64 (1996) 4561-4566
26. Leung M.Y., Liu C., Zhu L.F., Hui Y.Z., Yu B., and Fung K.P. Chemical and biological characterization of a polysaccharide biological response modifier from Aloe vera L. var. chinensis (Haw.) Berg. Glycobiology 14 (2004) 501-510
27. Ni Y., Turner D., Yates K.M., and Tizard I. Isolation and characterization of structural components of Aloe vera L. leaf pulp. Int Immunopharmacol 4 (2004) 1745-1755
28. Nose M., Terawaki K., Oguri K., Ogihara Y., Yoshimatsu K., and Shimomura K. Activation of macrophages by crude polysaccharide fractions obtained from shoots of Glycyrrhiza glabra and hairy roots of Glycyrrhiza uralensis in vitro. Biol Pharm Bull 21 (1998) 1110-1112
29. Guo Y., Matsumoto T., Kikuchi Y., Ikejima T., Wang B., and Yamada H. Effects of a pectic polysaccharide from a medicinal herb, the roots of Bupleurum falcatum L. on interleukin 6 production of murine B cells and B cell lines. Immunopharmacology 49 (2000) 307-316
30. Yaneva M.P., Botushanova A.D., Grigorov L.A., Kokov J.L., Todorova E.P., and Krachanova M.G. Evaluation of the immunomodulatory activity of Aronia in combination with apple pectin in patients with breast cancer undergoing postoperative radiation therapy. Folia Med 44 (2002) 22-25
31. Ebringerova A., Kardosová A., Hromádková Z., and Hríbalová V. Mitogenic and comitogenic activities of polysaccharides from some European herbaceous plants. Fitoterapia 74 (2003) 52-61
32. Ortega E., Algarra I., Serrano M.J., Alvarez de Cienfuegos G., and Gaforio J.J. The use of 7-amino-actinomycin D in the analysis of Candida albicans phagocytosis and opsonization. J Immunol Methods 253 (2001) 189-193
33. Norbury C., Hewlett L., Prescott A., Shastri N., and Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3 (1995) 783-791
34. Kim W.S., Ordija C.M., et al. Activation of signaling pathways by putative scavenger receptor class A (SR-A) ligands requires CD14 but not SR-A. Biochem Biophys Res Commun 310 (2003) 542-549
35. Czop J.K., and Austen K.F. A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J Immunol 134 (1985) 2588-2593
36. Czop J.K., and Kay J. Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. J Exp Med 173 (1991) 1511-1520
37. Brown G.D., Taylor P.R., et al. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 196 (2002) 407-412
38. Zamze S., Martinez-Pomares L., et al. Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the macrophage mannose receptor. J Biol Chem 277 (2002) 41613-41623
39. Ross G.D., and Vetvicka V. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 92 (1993) 181-184
40. Foss F.M. Immunologic mechanisms of antitumor activity. Semin Oncol 29 (2002) 5-11
41. Cohen I., Tagliaferri M., and Tripathy D. Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol 29 (2002) 563-574
42. Jatoi A., Ellison N., Burch P.A., Sloan J.A., Dakhil S.R., Novotny P., et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97 (2003) 1442-1446
43. Nahin R.L. Use of the best case series to evaluate complementary and alternative therapies for cancer: a systematic review. Semin Oncol 29 (2002) 552-562
44. Oh W.K., and Small E.J. Complementary and alternative therapies in prostate cancer. Semin Oncol 29 (2002) 575-584
45. Pongnikorn S., Fongmoon D., Kasinrerk W., and Limtrakul P.N. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy. J Med Assoc Thai 86 (2003) 61-68
46. Shen J., Andersen R., Albert P.S., Wenger N., Glaspy J., Cole M., et al. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2 (2002) 8
47. White J.D. Complementary and alternative medicine research: a National Cancer Institute perspective. Semin Oncol 29 (2002) 546-551
48. Yoshimura K., Ichioka K., Terada N., Terai A., and Arai Y. Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institute in Japan. Int J Clin Oncol 8 (2003) 26-30